Roche’s enicepatide helps patients with type 2 diabetes lose weight
Roche said its experimental obesity drug enicepatide helped patients with type 2 diabetes lose weight and lower blood sugar in a mid-stage clinical trial.
Roche Holding AG’s experimental obesity drug enicepatide helped patients with type 2 diabetes lose weight and reduce blood sugar levels in a mid-stage clinical trial, strengthening the Swiss drugmaker’s push to challenge established treatments from Eli Lilly and Novo Nordisk. Patients given the hi…